Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma

被引：12

作者：

Yang, Zijian ^{[1
]}

Suda, Goki ^{[1
]}

Maehara, Osamu ^{[2
]}

Ohara, Masatsugu ^{[1
]}

Yoda, Tomoka ^{[1
]}

Sasaki, Takashi ^{[1
]}

Kohya, Risako ^{[1
]}

Yoshida, Sonoe ^{[1
]}

Hosoda, Shunichi ^{[1
]}

Tokuchi, Yoshimasa ^{[1
]}

Kitagataya, Takashi ^{[1
]}

Suzuki, Kazuharu ^{[1
]}

Kawagishi, Naoki ^{[1
]}

Nakai, Masato ^{[1
]}

Sho, Takuya ^{[1
]}

Natsuizaka, Mitsuteru ^{[1
]}

Ogawa, Koji ^{[1
]}

Ohnishi, Shunsuke ^{[2
]}

Sakamoto, Naoya ^{[1
]}

机构：

[1] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo 0010021, Japan

[2] Hokkaido Univ, Fac Pharmaceut Sci, Lab Mol & Cellular Med, Sapporo 0010021, Japan

来源：

CANCERS | 2023年 / 15卷 / 03期

基金：

日本学术振兴会;

关键词：

resistance; mechanism; immune checkpoint inhibitor; atezolizumab; bevacizumab; hepatocellular carcinoma; progressive disease; VEGF-D; angiopoietin-2; SORAFENIB; VEGF;

D O I：

10.3390/cancers15030593

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC and the subsequent response to these therapies remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Growth factor changes between the baseline and best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies. The possible mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC, and the subsequent response to these therapies, remain underexplored. The sequential changes in serum growth factors, including VEGF-A, VEGF-C, VEGF-D, ANG-2, FGF-19, HGF, and EGF during atezolizumab/bevacizumab for unresectable HCC were evaluated in 46 patients. Patients who experienced PD after CR, PR, or SD to atezolizumab/bevacizumab were evaluated. A total of 4, 9, 19, and 14 patients showed CR, PR, SD, and PD, respectively. Of 32 patients with disease control, 28 experienced PD after CR, PR, or SD with atezolizumab/bevacizumab. Baseline growth factor levels were similar between patients with or without disease control and those with or without an objective response. Growth factor changes between the baseline and the best overall response points (BOR) for patients with disease control showed that FGF-19 significantly increased and ANG2 significantly decreased at the BOR. Growth factor changes between the BOR and the PD point in 28 patients who experienced PD after disease control showed that VEGF-D and ANG2 significantly increased at the PD point compared with that at the BOR. Summarily, increased serum VEGF-D and ANG-2 levels might contribute to developing resistance to atezolizumab/bevacizumab for unresectable HCC and might be target molecules in subsequent salvage therapies.

引用

页数：14

共 33 条

[1] VEGF in Signaling and Disease: Beyond Discovery and Development [J].

Apte, Rajendra S. ;

Chen, Daniel S. ;

Ferrara, Napoleone .

CELL, 2019, 176 (06) :1248-1264

[2] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[3] Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D [J].

Davydova, Natalia ;

Harris, Nicole C. ;

Roufail, Sally ;

Paquet-Fifield, Sophie ;

Ishaq, Musarat ;

Streltsov, Victor A. ;

Williams, Steven P. ;

Karnezis, Tara ;

Stacker, Steven A. ;

Achen, Marc G. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (53) :27265-27278

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[6] Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline [J].

Gordan, John D. ;

Kennedy, Erin B. ;

Abou-Alfa, Ghassan K. ;

Beg, Muhammad Shaalan ;

Brower, Steven T. ;

Gade, Terence P. ;

Goff, Laura ;

Gupta, Shilpi ;

Guy, Jennifer ;

Harris, William P. ;

Iyer, Renuka ;

Jaiyesimi, Ishmael ;

Jhawer, Minaxi ;

Karippot, Asha ;

Kaseb, Ahmed O. ;

Kelley, R. Kate ;

Knox, Jennifer J. ;

Kortmansky, Jeremy ;

Leaf, Andrea ;

Remak, William M. ;

Shroff, Rachna T. ;

Sohal, Davendra P. S. ;

Taddei, Tamar H. ;

Venepalli, Neeta K. ;

Wilson, Andrea ;

Zhu, Andrew X. ;

Rose, Michal G. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (36) :4317-+

[7] Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics [J].

Hegde, Priti S. ;

Wallin, Jeffrey J. ;

Mancao, Christoph .

SEMINARS IN CANCER BIOLOGY, 2018, 52 :117-124

[8] Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment [J].

Hosoda, Shunichi ;

Suda, Goki ;

Sho, Takuya ;

Ogawa, Koji ;

Kimura, Megumi ;

Yang, Zijian ;

Yoshida, Sonoe ;

Kubo, Akinori ;

Tokuchi, Yoshimasa ;

Kitagataya, Takashi ;

Maehara, Osamu ;

Ohnishi, Shunsuke ;

Nakamura, Akihisa ;

Yamada, Ren ;

Ohara, Masatsugu ;

Kawagishi, Naoki ;

Natsuizaka, Mitsuteru ;

Nakai, Masato ;

Morikawa, Kenichi ;

Furuya, Ken ;

Baba, Masaru ;

Yamamoto, Yoshiya ;

Suzuki, Kazuharu ;

Izumi, Takaaki ;

Meguro, Takashi ;

Terashita, Katsumi ;

Ito, Jun ;

Miyagishima, Takuto ;

Sakamoto, Naoya .

LIVER CANCER, 2023, 12 (02) :156-170

[9] Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors [J].

Ishikura, Nobuyuki ;

Sugimoto, Masamichi ;

Yorozu, Keigo ;

Kurasawa, Mitsue ;

Kondoh, Osamu .

ONCOLOGY REPORTS, 2022, 47 (02)

[10] Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab [J].

Iwai, Toshiki ;

Sugimoto, Masamichi ;

Patil, Namrata S. ;

Bower, Daniel ;

Suzuki, Miho ;

Kato, Chie ;

Yorozu, Keigo ;

Kurasawa, Mitsue ;

Shames, David S. ;

Kondoh, Osamu .

SCIENTIFIC REPORTS, 2021, 11 (01) :13912

← 1 2 3 4 →